Frequency of LATE neuropathologic change across the spectrum of Alzheimer’s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) and Alzheimer’s disease neuropathologic change (ADNC) are each associated with substantial cognitive impairment in aging populations. However, the prevalence of LATE-NC across the full range of ADNC remains uncertain. To address this knowledge gap, neuropathologic, genetic, and clinical data were compiled from 13 high-quality community- and population-based longitudinal studies. Participants were recruited from United States (8 cohorts, including one focusing on Japanese–American men), United Kingdom (2 cohorts), Brazil, Austria, and Finland. The total number of participants included was 6196, and the average age of death was 88.1 years. Not all data were available on each individual and there were differences between the cohorts in study designs and the amount of missing data. Among those with known cognitive status before death (n = 5665), 43.0% were cognitively normal, 14.9% had MCI, and 42.4% had dementia—broadly consistent with epidemiologic data in this age group. Approximately 99% of participants (n = 6125) had available CERAD neuritic amyloid plaque score data. In this subsample, 39.4% had autopsy-confirmed LATE-NC of any stage. Among brains with “frequent” neuritic amyloid plaques, 54.9% had comorbid LATE-NC, whereas in brains with no detected neuritic amyloid plaques, 27.0% had LATE-NC. Data on LATE-NC stages were available for 3803 participants, of which 25% had LATE-NC stage > 1 (associated with cognitive impairment). In the subset of individuals with Thal Aβ phase = 0 (lacking detectable Aβ plaques), the brains with LATE-NC had relatively more severe primary age-related tauopathy (PART). A total of 3267 participants had available clinical data relevant to frontotemporal dementia (FTD), and none were given the clinical diagnosis of definite FTD nor the pathological diagnosis of frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP). In the 10 cohorts with detailed neurocognitive assessments proximal to death, cognition tended to be worse with LATE-NC across the full spectrum of ADNC severity. This study provided a credible estimate of the current prevalence of LATE-NC in advanced age. LATE-NC was seen in almost 40% of participants and often, but not always, coexisted with Alzheimer’s disease neuropathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“TDP-43 pathology was discovered in 2006 as the primary pathological hallmark of frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) and amyotrophic lateral sclerosis [84].”
BackgroundMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894 · cited 2×
“Brain autopsies of persons with documented amnestic dementia often reveal evidence of Alzheimer’s disease neuropathologic change (ADNC) [69], limbic predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) [81], or both.”
BackgroundMethodSelf-citationNew insights into the genetic etiology of Alzheimer’s disease and related dementias
Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01024-z · Cited by 2,498 · cited 1×
“While there is heterogeneity in the genetic, pathologic, and clinical features of AD-type dementia [9, 41, 62, 71], there currently are no consensus-based criteria for delineating subtypes of ADNC.”
BackgroundSelf-citationStages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 2×
“Approximately 2/3rd of subjects in advanced age showed moderate or severe ADNC at brain autopsy, in concordance with the published literature [15].”
ResultNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 2×
“1 3 ADNC parameter that correlates most robustly with cognitive impairment [80].”
BackgroundSelf-citationPrevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656 · cited 1×
“Table 4 Joint distribution of LATE-NC positivity with CERAD neuritic amyloid plaque ratings [66] and Braak NFT stages [4, 13] Total without LATE-NC Total with LATE-NC LATE-NC, %”
Method
Cited by
Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS
(2024) · doi:10.1038/s41591-024-02937-4 · Cited by 217
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Boxer, A. L., & Sperling, R. (2023) · Cell · doi:10.1016/j.cell.2023.09.023 · Cited by 197
Nichols, E., Merrick, R., Hay, S. I., Himali, D., Himali, J. J., Hunter, S., Keage, H. A. D., Latimer, C. S., Scott, M. R., Steinmetz, J. D., et al. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00019-3 · Cited by 108
Self-citationShade, L. M. P., Katsumata, Y., Abner, E. L., Aung, K. Z., Claas, S. A., Qiao, Q., Heberle, B. A., Brandon, J. A., Page, M. L., Hohman, T. J., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01939-9 · Cited by 72
“Although LATE-NC is diagnostically characterized by TDP-43 proteinopathy 3,12,13 , brains with a greater burden of neuritic amyloid plaques are more likely to have TDP-43 proteinopathy (and vice versa) 12 .”
Self-citationGranulin loss of function in human mature brain organoids implicates astrocytes in TDP-43 pathology
de Majo, M., Koontz, M., Marsan, E., Salinas, N., Ramsey, A., Kuo, Y.-M., Seo, K., Li, H., Dräger, N., Leng, K., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.01.012 · Cited by 44
Huang, Z., Merrihew, G. E., Larson, E. B., Park, J., Plubell, D., Fox, E. J., Montine, K. S., Latimer, C. S., Dirk Keene, C., Zou, J. Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38376-x · Cited by 37
Self-citationWalker, J. M., & Richardson, T. E. (2023) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac115 · Cited by 26
Amyloid-β predominant Alzheimer’s disease neuropathologic change
Kovacs, G. G., Katsumata, Y., Wu, X., Aung, K. Z., Fardo, D. W., Forrest, S. L., Alzheimer's Disease Genetics Consortium, Bowen, J. D., Crane, P. K., Jarvik, G. P., et al. (2025) · Brain · doi:10.1093/brain/awae325 · Cited by 19
Self-citationDaneshvar, D. H., Nowinski, C. J., Abdolmohammadi, B., Luster, C. B., Uretsky, M., Martin, B. M., Palmisano, J. N., Weuve, J., McClean, M. D., Cherry, J. D., et al. (2026) · BMJ · doi:10.1136/bmj-2026-100418 · Cited by 17
“…1 2 compare prevalences of dementia and neurodegenerative disease as determined by study clinician adjudication versus death certificates, 3 and estimate the association of stage IV CTE disease at death with dementia to examine the extent to which CTE neuropathological findings…”
Self-citation
Metadata
- Authors
- Nelson, P. T., Brayne, C., Flanagan, M. E., Abner, E. L., Agrawal, S., Attems, J., Castellani, R. J., Corrada, M. M., Cykowski, M. D., Di, J., Dickson, D. W., Dugger, B. N., Ervin, J. F., Fleming, J., Graff-Radford, J., Grinberg, L. T., Hokkanen, S. R. K., Hunter, S., Kapasi, A., Kawas, C. H., Keage, H. A. D., Keene, C. D., Kero, M., Knopman, D. S., Kouri, N., Kovacs, G. G., Labuzan, S. A., Larson, E. B., Latimer, C. S., Leite, R. E. P., Matchett, B. J., Matthews, F. E., Merrick, R., Montine, T. J., Murray, M. E., Myllykangas, L., Nag, S., Nelson, R. S., Neltner, J. H., Nguyen, A. T., Petersen, R. C., Polvikoski, T., Reichard, R. R., Rodriguez, R. D., Suemoto, C. K., Wang, S.-H. J., Wharton, S. B., White, L., & Schneider, J. A.
- Venue
- Acta Neuropathologica
- Published
- 2022-06-13
- Volume
- 144
- Issue
- 1
- Pages
- 27-44
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W4282596629
- Cited by
- 174
- References
- 41
- FWCI
- 19.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.